Tissue Regenix Group PLC (FRA:LSW)
€ 0.71 0.005 (0.71%) Market Cap: 53.33 Mil Enterprise Value: 59.91 Mil PE Ratio: 0 PB Ratio: 1.85 GF Score: 43/100

Full Year 2023 Tissue Regenix Group PLC Earnings Call Transcript

Mar 19, 2024 / 11:00AM GMT
Release Date Price: €0.77
Operator

Good morning, and welcome to the Tissue Regenix Group plc full year investor presentation(Operator Instructions) I'd now like to hand over to Daniel Lee, CEO, good morning to you, sir.

Daniel Lee
Tissue Regenix Group PLC - Chief Executive Officer

Good morning and good morning, to everybody who has joined us on this webinar. Thank you for spending some time with us. David Cocke, and I will provide you an update on Tissue Regenix as we just released our 2023 results.

So we'll spend the next 30 minutes updating you on the company, our activities as well as our plans. We'll have time for questions at the end. So the standard disclaimer slide, which I encourage all of you to review a little bit of an introduction about myself and David, I'm Daniel Lee, I'm the Chief Executive Officer for Tissue Regenix. I was appointed CEO in November of 2020, but prior to that, I joined the Tissue Regenix Group as the President of US Operations for the cell actions for the cell right division.

There's no rate division of Tissue Regenix was acquired in 2017. I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot